LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Accueil・Liste d'Actions・Crinetics Pharmaceuticals Inc
Search

Crinetics Pharmaceuticals Inc

Fermé

SecteurSoins de santé

32.42 -6.03

Achat Fort

Actualisation du prix 2 juin 2026, 19:59 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.26

Max

34.15

Chiffres clés

By Trading Economics

Revenu

-5M

-128M

Ventes

6.8M

11M

BPA

-1.23

Marge bénéficiaire

-1,191.029

Employés

594

EBITDA

-18M

-139M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+155.33% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-469M

3.9B

Ouverture précédente

38.45

Clôture précédente

32.42

Sentiment de l'Actualité

By Acuity

87%

13%

310 / 344 Classement par Healthcare

Crinetics Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2026, 20:30 UTC

Résultats

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

DJ

Lire

3 juin 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

DJ

Lire

3 juin 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

DJ

Lire

3 juin 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

DJ

Lire

3 juin 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

DJ

Lire

2 juin 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

DJ

Lire

2 juin 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Lire

2 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

DJ

Lire

2 juin 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

DJ

Lire

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

DJ

Lire

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

DJ

Lire

2 juin 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

DJ

Lire

2 juin 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

DJ

Lire

2 juin 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

DJ

Lire

2 juin 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lire

2 juin 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

DJ

Lire

2 juin 2026, 21:00 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

DJ

Lire

2 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Lire

2 juin 2026, 20:46 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

DJ

Lire

2 juin 2026, 20:38 UTC

Résultats

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

DJ

Lire

2 juin 2026, 20:21 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

DJ

Lire

2 juin 2026, 20:12 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Product Rev $594M

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

DJ

Lire

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

DJ

Lire

Comparaison

Variation de prix

Crinetics Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

155.33% hausse

Prévisions sur 12 Mois

Moyen 88.14 USD  155.33%

Haut 97 USD

Bas 81 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

8

Achat

0

Maintien

0

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

310 / 344Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

1,063.79

↓-1.23%

JNJ

Johnson and Johnson

222.81

↓-0.32%

ABBV

AbbVie Inc

215.58

↑ +1.54%

UNH

UnitedHealth Group Inc

377.18

↓-0.59%

MRK

Merck & Co Inc.

115.96

↑ +0.86%
help-icon Live chat